Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CML, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J; International Radiogenomics Consortium (RgC). Andreassen CN, et al. Among authors: vesprini d. Radiother Oncol. 2016 Dec;121(3):431-439. doi: 10.1016/j.radonc.2016.06.017. Epub 2016 Jul 18. Radiother Oncol. 2016. PMID: 27443449 Free PMC article.
Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C. Vesprini D, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e415-21. doi: 10.1016/j.ijrobp.2011.01.024. Epub 2011 Apr 7. Int J Radiat Oncol Biol Phys. 2011. PMID: 21477939 Clinical Trial.
MRI-guided prostate adaptive radiotherapy - A systematic review.
McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, Mahmood U, Pos F, van As N, van Herk M, Vesprini D, van der Voort van Zyp J, Tree A, Choudhury A; MR-Linac consortium. McPartlin AJ, et al. Among authors: vesprini d. Radiother Oncol. 2016 Jun;119(3):371-80. doi: 10.1016/j.radonc.2016.04.014. Epub 2016 May 6. Radiother Oncol. 2016. PMID: 27162159 Review.
Treatment Outcomes in Male Breast Cancer: A Retrospective Analysis of 161 Patients.
Wan BA, Ganesh V, Zhang L, Sousa P, Drost L, Lorentz J, Vesprini D, Lee J, Rakovitch E, Lu FI, Eisen A, Yee C, Lam H, Chow E. Wan BA, et al. Among authors: vesprini d. Clin Oncol (R Coll Radiol). 2018 Jun;30(6):354-365. doi: 10.1016/j.clon.2018.02.026. Epub 2018 Mar 2. Clin Oncol (R Coll Radiol). 2018. PMID: 29496323
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A. Quon HC, et al. Among authors: vesprini d. Radiother Oncol. 2018 May;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. Epub 2018 Mar 15. Radiother Oncol. 2018. PMID: 29551231 Clinical Trial.
158 results